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Abstract: Background: The prognosis of early stage non-small cell lung cancer (NSCLC) is quite
disappointing and the benefits of adjuvant therapy are relatively small. Thus, there is an urgent
need to identify novel prognostic and predictive biomarkers. Lung adenocarcinoma has distinct
clinical–pathological characteristics and novel therapeutic strategies are under active evaluation
in the adjuvant setting. Here, we investigated the prognostic impact of circulating tumor cells
(CTCs) and gene and miRNA tissue expression in resectable NSCLC. Patients and methods: We
assessed the association between CTC subpopulations and the outcome of resected early stage
lung adenocarcinoma (ADC) patients at three different time-points (CTC1-3) (before surgery, after
one month, and after six months) in comparison to squamous cell carcinoma (SCC). Furthermore,
gene and miRNA tissue expression, immunoprofiling, and epithelial-to-mesenchymal transition
(EMT) markers were correlated with outcome. Results: ADC (n = 47) and SCC (n = 50) revealed
different tissue expression profiles, resulting in the presence of different CTC subpopulations. In ADC,
miR-155 correlated with AXL and IL6R expression, which were related to the presence of EMT CTC1
(p = 0.014 and p = 0.004). In the multivariate analysis, CTC2 was an independent prognostic factor
for relapse-free survival, and CTC3 and AXL were independent prognostic for overall survival only
in ADC. Neither the surgery nor the adjuvant treatment influenced the prognosis of these patients.
Conclusions: Our study elucidate the prognostic impact of tissue AXL expression and the presence of
CTCs after surgery in adenocarcinoma patients. Tissue AXL expression and CTC EMT activation
could potentially represent biomarkers for the stratification of ADC patients that might benefit from
new adjuvant therapies.
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1. Background
Surgery is the mainstay of treatment for early stage non-small cell lung carcinoma (NSCLC) (stage
I-IIIA), and the addition of platinum-based chemotherapy, either as adjuvant or neo-adjuvant therapy,
has been associated with a modest but significant survival benefit [1]. Despite major breakthroughs
in lung cancer biology and drug development in advanced/metastatic NSCLC, treatment of early
stage disease has changed little over the last two decades [2]. The prognosis of resected NSCLC
patients is highly heterogeneous and a proportion of stage IA patients, which are not candidate to
adjuvant therapy, still recur after surgical resection. Furthermore, a high grade of heterogeneity
exists in the outcome of stage IB-IIIA patients, even after aggressive post-surgical treatments that can
include platinum-based chemotherapy with or without radiotherapy in selected cases. The biological
mechanisms underlying these differences are not completely understood.
Large whole exome sequencing studies revealed that squamous cell lung cancer (SCC) and lung
adenocarcinoma (ADC) have distinct patterns of somatic genome alterations [3], as well as the clinical
significance of intratumor heterogeneity, which could be therapeutically exploited [4]. In addition,
ADC and SCC subtypes differ in prognosis and progression. In fact, SCC patients have lower survival
rates after surgery [5]. These differences might be explained by the tumor mutation burden (TMB), as
high nonsynonymous TMB was a favorable prognostic factor in resected NSCLC [6]. Nevertheless,
despite the increasing knowledge about the biological behavior of these subtypes, the differences in
the aggressiveness pattern between SCC and ADC are not clear yet.
Moreover, it is well known that circulating tumor cells (CTCs) contribute to tumor aggressiveness
in advanced disease, disseminating through the blood to distant sites contributing to the process
of metastatization of solid tumors, including NSCLC [7,8]. In contrast, only a few studies to date
have evaluated the prognostic impact of CTCs in early stages of NSCLC [9–11]. However, the
capacity of these CTCs to survive in different microenvironments and their success in colonizing new
organs depends on the acquisition of genetic and phenotypic traits. This might be caused by the
epithelial–mesenchymal transition (EMT) that, in neoplasias, consists of a cellular reprogramming
that transforms epithelial cancer cells into mesenchymal or semi-mesenchymal cancer cells, allowing
them to detach from the tumor and to disseminate into the blood. When the EMT is induced, the
expression of transcriptions factors such as Zeb1 or Snail is increased. This, in turn, causes the
loss of their classical polygonal morphology and the decrease in the expression of proteins such as
E-cadherin. In exchange, they acquire a spindle-shaped morphology that is associated with an increase
of mesenchymal proteins, such as vimentin and AXL. In addition, EMT has been associated with
increased resistance to chemotherapy, targeted therapies, and immunotherapy [12,13].
As a consequence, heterogeneous subpopulations of CTCs can be found in the same patient [14].
In the current work, we analyze the presence of epithelial cells and mesenchymal cells and characterize
their expression of epidermal growth factor receptor (EGFR), the overexpression of which has been
associated with higher aggressiveness of NSCLC. On the other hand, microRNAs (miRNAs) are key
regulators of gene expression and are therefore responsible for the phenotypical changes of tumor
cells [15]. Specifically, miRNAs have pleiotropic actions and play key roles in several cellular processes,
including cell proliferation, invasion, and EMT. Furthermore, miRNAs act as mediators of cell–cell
communication and immune regulation. Aberrant miRNAs expression has been associated with
several pathological conditions, including lung cancer, acting as biomarkers involved in the disease
progression [16,17].
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The aim of this study is to identify the specific correlation between gene and miRNA tissue
expression with the release of CTC subpopulations and their role as prognostic biomarkers in
adenocarcinoma and squamous cell carcinoma patients undergoing complete surgical resection.
2. Patients and Methods
Study Design and Patients
We conducted a prospective longitudinal cohort study in early stage NSCLC patients (I-IIIA)
who underwent anatomical pulmonary resection and systematic lymph node dissection with curative
intent at the University Hospital of Granada (Spain), between November 2012 and February 2015
(Supplementary Materials Text 1). Patients with concurrent or prior malignancy in the previous five
years, with prior induction chemotherapy or radiotherapy, or who died within 30 days from the surgery
were excluded. Pathological stage was defined according to the international tumor-node-metastasis
(TNM) system seventh edition [18], which was the current version at the time of sample collection
and histological diagnosis was posed using the World Health Organization classification. Indication
for adjuvant treatment was established by the Local Tumor Committee according to the American
Society of Clinical Oncology (ASCO) guidelines [19] and consisted of four cycles of platinum doublets.
Clinical outcomes were evaluated in terms of relapse-free survival (RFS) and overall survival (OS).
RFS was defined as the time from surgery until first recurrence (loco-regional or distant metastasis) or
death due to any cause, while OS was the time from surgery until death due to any cause. Fresh tissue
from the tumor pulmonary resection and 15 mL of peripheral blood were collected from each patient.
Peripheral blood samples were extracted before surgery (2–16 h) (CTC1), one month later (CTC2), and
six months later (CTC3) (during adjuvant treatment in those susceptible cases) (Figure 1A). Tissue and
blood samples were analyzed at the GENyO Centre (Centre for Genomic and Oncological Research,
Granada, Spain). In addition, this study included nine initially suspicious lung cancer patients that
were confirmed as non-tumor in the resection and were used as tissue genetic expression controls and
CTC negative controls.
This study was approved by the Institutional Ethical Committee (Comité de Ética de la
Investigación de Centro de Granada, CEI-GRANADA, Granada, Spain) on 26 July 2012 (ethic code:
27072012). Written informed consent was obtained from all cancer patients and healthy volunteers
prior to inclusion in this study. Clinical studies were completed under good clinical and laboratory
practice conditions in accordance with local standards.
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Figure 1. Study design and circulating tumor cell (CTC) characterization. (A) Patients enrolled and 
study design: this study included two cohorts, one of adenocarcinoma (ADC) and the other of 
squamous cell carcinoma (SCC) patients with similar distributions of gender, stage, and administered 
adjuvant treatment. Baseline blood sample (CTC1) was extracted before the surgery and tissue 
collection, one month after (CTC2), and six months later (CTC3) during adjuvant treatment in those 
susceptible cases (Credit: created with BioRender). (B) Immunofluorescence of CTC phenotype 
characterization in non-small cell lung cancer (NSCLC) patients: top row shows a cytokeratin-positive 
CTC (green and red staining) with epidermal growth factor receptor (EGFR) positive expression 
(blue). Bottom row represents an epithelial-to-mesenchymal transition (EMT) CTC with vimentin 
expression (green), EGFR positive expression (red), and DAPI—nuclei staining (blue). Images taken 
at 63× magnification in a Zeiss Epifluorescence Axio Imager A.1 microscope. 
3. Materials and Methods 
3.1. Isolation and Characterization of CTCs 
Peripheral blood samples (15 mL) were collected in EDTA tubes, stored at room temperature, 
and processed within 4 h after blood sampling. CTCs were isolated according to the previously 
established protocol by our group [11]. Briefly, blood samples were subjected to density gradient 
centrifugation and immunomagnetic isolation of epithelial cells with the Carcinoma Cell Enrichment 
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month after (CTC2), and six months later (CTC3) during adjuvant treatment in those susceptible cases
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non-small cell lung cancer (NSCLC) patients: top row shows a cytokeratin-positive CTC (green and
red staining) with epidermal growth facto recept r (EGFR) positive expression (blue). Bottom row
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Zeiss Epifluorescence Axio Imager A.1 microscope.
3. Materials and Methods
3.1. Isolation and Characterization of CTCs
Peripheral blood samples (15 mL) were collected in EDTA tubes, stored at room temperature, and
processed within 4 h after blood sampling. CTCs were isolated according to the previously established
protocol by our group [11]. Briefly, blood samples were subjected to density gradient centrifugation
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and immunomagnetic isolation of epithelial cells with the Carcinoma Cell Enrichment and Detection
Kit with MACS Technology (Miltenyi Biotec, Bergisch Gladbach, Germany), based on multicytokeratin
antibody (CK3-11D5), which recognizes cytoplasmic cytokeratins 7, 8, 18, and 19. Each sample was
spun down onto two slides in a cytocentrifuge (Hettich) and identified by immunocytochemical and
chromogenic assays. Epithelial tumor cells were identified and counted based on their red staining. In
positive slides, EGFR expression was analyzed by immunofluorescence [7]. On the other hand, in 54
baseline samples, MACS column elutes could be collected and subjected to a second immunomagnetic
selection based on vimentin expression. Immunofluorescence techniques were applied to isolate and
characterize EMT cells (EMT CTC1) (Figure 1B) (Supplementary Materials Text 2).
3.2. Tissues Total RNA Extraction and cDNA Synthesis
Fresh tissues were stored at −80 ◦C in RNA later Tissue Protect Tubes (Qiagen, Hilden, Germany)
until total RNA was extracted with TRIzolTM Reagent (Invitrogen, Waltham, MA, USA), according to
manufacturer’s instructions. RNA concentration and purity were determined using NanoDrop 2000c
Spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA), 1 µg of total RNA was converted
to complementary DNA (cDNA) according to the QuantiTect Reverse Transcription Kit (Qiagen) for
subsequent RNA expression, and 10 ng of total RNA was converted to cDNA according to TaqManTM
Advanced miRNA cDNA Synthesis Kit (ThermoFisher Scientific) for miRNAs analysis.
3.3. Quantitative (Real Time) Polymerase Chain Reaction for mRNA and miRNA Expression
Five genes were selected based on their reported association with tumor migration, aggressiveness,
treatment resistance, immune response, and progression in NSCLC tumors (AXL, IL6R, MET, and
GAPDH) [20–23]. In addition, five miRNAs (miR-21-5p, 222-3p, 155-5p, 24-3p, 30c-5p) were identified
on their reported association with biological tumor characteristics and cisplatin/targeted therapies
efficacy [16,24,25]. qRT-PCR primers were designed spanning exon–exon boundaries (Sigma-Aldrich,
St. Louis, MO, USA), details in Supplementary Table S1.
In addition, B2M and miR-16 were selected as endogenous controls using Normfinder version
20 [26] and geNorm VBA applet for Microsoft Excel [27]. Gene expression was measured using
the PerfeCta SYBR Green FastMix, Rox (Quanta Biosciences, Beverly, MA, USA) on a TaqMan 7900
HT Real-Time PCR system (Life Technologies, Carlsbad, CA, USA). Expression levels of miRNAs
were measured using TaqManTM MicroRNA assays probes and TaqManTM Universal PCR Master
Mix (ThermoFisher Scientific) in the same PCR System. Each test was run three times and included
non-template controls (NTC). Expression levels are shown as 2−∆∆Ct [28].
3.4. Statistical Analyses
CTCs were assessed as a continuous (number of CTCs) and as a binary variable (presence
(CTCs ≥ 1)/absence). Cut-offs to distinguish between high and low levels of miRNA and gene
expression were determined using the survival analysis of the Cutoff Finder web application [29].
The Kolmogórov–Smirnov test was applied and data were analyzed by Fisher’s exact test and
non-parametric Kruskal–Wallis, Mann–Whitney U-test, and Spearman’s rank correlation tests.
Univariate Kaplan–Meier (log-rank test) was used to analyzed CTC influence on RFS and OS,
while Cox proportional hazard regression was applied for the multivariate analyses. Criterion of more
than a 10% change in the variable coefficient estimate for the selection of variables to be included
in the multivariate model was applied [30]. Statistical analyses were performed using IBM SPSS
Statistics (version 22.0 for Windows, IBM Corp., Armonk, NY, USA) and graphs using GraphPad Prism
(version 7.04 for Windows, GraphPad software, La Jolla, CA, USA). A p-value of <0.05 was considered
statistically significant.
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4. Results
A total of 97 consecutive NSCLC patients were enrolled in this study, including 47 ADC patients
(median follow-up 30.5 months, range 3–50), and 50 SCC patients were used as a comparative NSCLC
subpopulation (median follow-up 32 months, range 3–49). Clinical–pathological characteristics of
both cohorts are summarized in Table 1. The two groups were well balanced, with no differences in
terms of tumor stage and the proportion of patients undergoing adjuvant therapy (Figure 1A). As
expected, the SCC group was associated with a lower percentage of women, larger tumor size, higher
positron emission tomography—maximum standardized uptake values (PET SUVmax), and a higher
percentage of pneumonectomy treatment compared with ADC.
Table 1. Clinical–pathological and treatment-related characteristics of NSCLC patients by
histological type.
Characteristics NSCLC n = 97 (%) ADC n = 47 (%) SCC n = 50 (%) p
Gender
Men 84 (86.6%) 36 (76.6%) 48 (96%)
0.005Women 13 (13.4%) 11 (23.4%) 2 (4%)
Age (years)
Mean ± SD 66.13 ± 8.65 65.49 ± 9.64 66.7 ± 7.6
<70 58 (59.8%) 28 (59.6%) 30 (60%)
0.966≥70 39 (40.2%) 19 (40.4%) 20 (40%)
Smoking habits
Never smoker 9 (9.3%) 7 (14.9%) 2 (4%)
0.168Ex-smoker 62 (63.9%) 11 (23.4%) 15 (30%)
Current smoker 26 (26.8%) 29 (61.7%) 33 (66%)
Stage
I 44 (45.4%) 23 (48.9%) 21 (42%)
0.700II 25 (36.1%) 15 (31.9%) 20 (40%)
III 18 (18.6%) 9 (19.1%) 9 (18%)
N status
N0 71 (73.2%) 34 (72.3%) 37 (74%)
0.909N1 15 (15.5%) 8 (17%) 7 (14%)
N2 11 (11.3%) 5 (10.6%) 6 (12%)
Tumor size (cm)
Mean ± SD 4.03 ± 2.13 3.52 ± 2.1 4.5 ± 2.1
≤4 cm 54 (55.8%) 31 (57.4%) 23 (42.6%)
0.048
>4 cm 43 (44.3%) 16 (37.2%) 27 (62.8%)
PET (SUVmax)
Mean ± SD 11.05 ± 5.67 9.16 ± 5.06 12.74 ± 5.69
≤9.4 47 (49.5%) 30 (66.7%) 17 (34%)
0.002
>9.4 48 (50.5%) 15 (33.3%) 33 (66%)
Surgical approach
Thoracotomy 57 (58.8%) 23 (48.9%) 34 (68%)
0.057VATS 40 (41.2%) 24 (51.1%) 16 (32%)
Type of resection
Lobectomy 80 (82.5%) 43 (91.5%) 37 (74%)
0.024Pneumonectomy 17 (17.5%) 4 (8.5%) 13 (26%)
Adjuvant chemotherapy
No 59 (60.8%) 28 (59.6%) 31 (62%)
0.807Yes 38 (39.2%) 19 (40.4%) 19 (38%)
Adjuvant radiotherapy
No 91 (93.8%) 44 (93.6%) 47 (94%)
0.938Yes 6 (6.2%) 3 (6.4%) 3 (6%)
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Table 1. Cont.
Characteristics NSCLC n = 97 (%) ADC n = 47 (%) SCC n = 50 (%) p
CTC1
Mean (SD) Range 2.13 (± 8.7) 0–84 1.3 (± 2.6) 0–11 2.92 (± 11.9) 0–84
Absence 57 (48.8%) 32 (68.1%) 25 (50%)
0.071Presence 40 (41.2%) 15 (31.9%) 25 (50%)
CTC2
Mean (SD) Range 0.74 (± 1.6) 0–10 0.74 (± 1.9) 0–10 0.74 (± 1.2) 0–4
Absence 70 (72.2%) 35 (74.5%) 35 (70%)
0.624Presence 27 (27.8%) 12 (25.5%) 15 (30%)
CTC3
Mean (SD) Range 0.7 (± 1.8) 0–9 0.88 (± 2.1) 0–9 0.55 (± 2.8) 0–8
Absence 57 (81.4%) 25 (78.1%) 32 (84.2%)
0.514Presence 13 (18.6%) 7 (21.9%) 6 (15.8%)
CTC1 EMT NSCLC n = 54 (%) ADC n = 22 (%) SCC n = 32 (%)
Mean (SD) Range 0.3 (± 0.44) 0–3 0.14 (± 0.4) 0–1 0.41 (± 0.8) 0–3
Absence 43 (79.6%) 19 (86.4%) 24 (75%)
0.308Presence 11 (20.4%) 3 (13.6%) 8 (25%)
p: p-value of Fisher’s exact test between ADC and SCC; SD: Standard Deviation; TNM: Tumor Node Metastasis; N:
node; PET (SUVmax): positron emission tomography—maximum standardized uptake values; VATS: video-assisted
thoracic surgery.
4.1. Isolation and Characterization of CTCs
To evaluate the suitability of CTCs as prognostic factors in ADC and SCC patients, we isolated
and characterized the different subtypes of CTCs before surgical resection (epithelial CTC1 and EMT
CTC1) and during the follow-up (epithelial CTC2 and CTC3) (Figure 1B). No CTC was found in the
control group of non-tumor patients. We compared the presence of CTCs at different time points
in ADC and SCC, observing no significant differences between the two groups (Table 1). Moreover,
clinical–pathological variables were compared to the presence of different phenotypes of CTCs at the
different time points. In ADC patients, the presence of CTC2 was related to higher stages (p = 0.006),
while the presence of CTC3 and EMT CTC1 was correlated with higher N stage (p = 0.017 and
p = 0.007). On the contrary, no association was found between CTCs and clinical–pathological variables
in SCC patients.
EGFR expression was analyzed in epithelial and EMT CTCs as observed in (Figure 1B). The
frequency of patients with EGFR positive CTCs and the absolute number of these and other CTCs along
the follow-up can be found in the Supplementary Table S2. All EMT CTCs had positive expression of
EGFR. Moreover, in the 54 patients where both epithelial (CTC1) and EMT (EMT CTC1) were analyzed,
16 EMT and 130 epithelial CTCs were found. This resulted in a ratio of 1 EMT per 9.13 epithelial CTCs.
4.2. Genetic and miRNA Tissue Profiling and CTC Subpopulations
We analyzed the specific tumor tissue miRNA and gene interactions involved in the pathogenesis
of ADC versus SCC and the release of different subpopulations of CTCs in ADC patients in comparison
to SCC. Interestingly, we observed specific correlations in ADC, as miR-155 inversely correlated with
IL6R and AXL (p = 0.003 and p = 0.034, respectively) and, in contrast, MET expression positively
correlated with miR-24 (p = 0.005) and miR-30c (p = 0.040) (Figure 2A). We found that higher expression
of IL6R, AXL, and GAPDH correlated with the presence of EMT + CTC1 in these patients (p = 0.004,
p = 0.014, and p = 0.021, respectively) (Figure 2B). On the other hand, no gene/miRNA and CTC
correlation was observed in SCC patients.
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between selected miRNAs and genes in ADC (top-right corner) and in SCC (bottom-left corner). Data 
represent Spearman’s rho and (p-value). p < 0.05 in bold. Pink tones show positive correlations, yellow 
neutral, and green tones show negative correlations. (B): Blox-plot of gene tissue expression 
relationship with CTC phenotypes in ADC. Pattern fill colors represent the presence of CTC versus 
plain colors showing absence. Mann–Whitney U-test. * p < 0.05, ** p < 0.01. 
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Figure 2. Genetic and miRNA tissue profiling and CTC correlation in ADC: (A): Heat-map correlation
between selected miRNAs and genes in ADC (top-right corner) and in SCC (bottom-left corner). Data
represent Spearman’s rho and (p-value). p < 0.05 in bold. Pink tones show positive correlations,
yellow neutral, and green tones show negative correlations. (B): Blox-plot of gene tissue expression
relationship with CTC phenotypes in ADC. Pattern fill colors represent the presence of CTC versus
plain colors showing absence. Mann–Whitney U-test. * p < 0.05, ** p < 0.01.
4.3. Prognostic Markers of Relapse-Free Survival
A total of 23 (48.9%) ADC patients and 19 (38%) SCC patients relapsed during the follow-up
(median follow-up 28 and 27.5 months, respectively). No significant differences were observed in the
RFS between the two histological subtypes (p = 0.911).
In the Kaplan–Meier analysis, the presence of CTC2 (Hazard Ratio (HR) = 4.34, p = 0.037) and
high tissue levels of AXL (HR = 4.54, p = 0.033) were associated with worse RFS (Figure 3A,B) in
ADC patients. AXL expression ranged from 2−∆∆Ct = 0.088 to 10.895 and high levels were defined as
2−∆∆Ct ≥ 1.796. The univariate Cox’s regression analysis was performed for each clinical–pathological
and experimental variable. However, pneumonectomy (p = 0.047), N1 status (p = 0.06), adjuvant
radiotherapy (p = 0.059), presence of CTC2 (p = 0.046), and high levels of AXL (p = 0.044) were the only
variables associated with higher relapse risk in ADC patients (Supplementary Table S3). The EGFR
CTCs, miRNAs, and other genes analyzed showed no statistical association. Neither the adjuvant
chemotherapy nor the post-operative radiotherapy affected RFS. In the multivariate analysis, the
presence of CTCs after surgery (CTC2) correlated with shorter RFS (Figure 3C) and was an independent
prognostic factor for RFS in ADC patients (HR = 2.51, 95% CI = 1.07–5.87, p = 0.034) (Table 2).
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Figure 3. CTCs as relapse prognostic biomarkers and their dynamics in ADC: (A) Kaplan–Meier of the
influence of CTC2 in the relapse-free survival (RFS). Patients with the presence of CTC2 had 4.34 times
higher risk of developing relapse after the surgery versus those without them. Log-rank (Mantel–Cox)
test was applied. (B) Kaplan–Meier of the influence of AXL tissue expression in the RFS. Patients
with high AXL had 4.54 times higher risk of developing relapse after the surgery versus those with
low expression. Log-rank (Mantel–Cox) test was applied. (C) Swimmer plot showing shorter RFS
in patients with presence of CTCs after surgery (CTC2) (orange) versus patients with an absence of
these cells (light blue). Follow-up after recurrence is represented in dark blue. Adjuvant therapy
was administered after CTC2 extraction in those highlighted with red arrows, finding no significant
differences according to the treatment between the two groups.
Table 2. Final multivariate Cox proportional hazards regression model for RFS and OS in ADC and SCC.
ADC
RFS HR 95% CI p OS HR 95% CI p
Resection
type Relapse
Pneumonectomy 4.23 1.13–15.8 0.032 Yes 15.0 1.04–216.2 0.047
Lobectomy 1.00 No 1.00
CTC2 PET(SUVmax)
Presence 2.51 1.07–5.87 0.034 >9.4 6.4 0.96–42.5 0.055
Absence 1.00 ≤9.4 1.00
CTC3
Presence 10.8 1.54–76.4 0.017
Absence 1.00
AXL
High 15.7 1.63–150.7 0.017
Low 1.00
SCC
Size (cm) Relapse
>4cm 6.77 1.94–23.56 0.003 Yes 6.42 2.17–19.04 0.001
≤4cm 1.00 No 1.00
N status N status
N0 1.00 0.192 N0 1.00 0.075
N1 2.72 0.92–7.98 0.070 N1 1.37 0.41–4.60 0.609
N2 1.26 0.28–5.84 0.764 N2 3.54 1.19–10.59 0.024
RFS: Relapse-free survival; OS: Overall survival; HR: hazard ratio; CI: confidence interval; p: p-value; PET (SUVmax):
positron emission tomography—maximum standardized uptake values.
On the contrary, no CTC subgroup or other experimental biomarkers were related to RFS in the
SCC group (Supplementary Table S3). Tumor size and N status were the only independent prognostic
factors for RFS in SCC patients (Table 2).
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4.4. Prognostic Markers of Overall Survival: Elucidating the Role of AXL
A total of 18 (38.3%) ADC patients and 19 (38%) SCC patients died during the follow-up period
(median follow-up 30.5 and 32 months, respectively), with no significant difference in OS between the
two groups (p = 0.715). In the Kaplan–Meier analysis, the presence of CTC3 (HR = 3.62, p = 0.057) and
high levels of tissue AXL (HR = 8.51, p = 0.004) were associated with a worse prognosis (Figure 4A,B)
in ADC patients. When combined, CTC3+ and/or AXL-high patients had the shortest OS (HR = 9.42,
p = 0.002) (Figure 4C).
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Figure 4. CTCs and tissue AXL as survival prognostic biomarkers in ADC: (A): Kaplan–Meier of the
influence of CTC3 in the OS. Patients with presence of CTC3 had 3.62 times higher risk of exitus versus
those without them. Log-rank (Mantel–Cox) test was applied. (B): Kaplan–Meier of the influence
of AXL tissue expression in the OS. Patients with high AXL levels had an 8.51 times higher risk of
exitus versus those with low levels. Log-rank (Mantel–Cox) test was applied. (C): Kaplan–Meier of the
influence of CTC3 and AXL tissue expression in the OS. Patients with high AXL levels or presence of
CTC3 had a 9.42 times higher risk of exitus versus patients with low AXL and negative CTC3. Log-rank
(Mantel–Cox) test was applied. (D): Waterfall plot showing how presence of CTC3 (six months after
surgery) (yellow), high AXL tissue expression (red), and both (orange) predicts OS in ADC patients,
regardless adjuvant treatment administration (star).
As previously reported for the RFS, each clinical–pathological and experimental variable was
analyzed in the univariate analysis for OS. However, the presence of CTC2 was not an independent
factor for OS. On the other hand, the presence of CTC3 (p = 0.072), high tissue AXL levels (p = 0.007),
and high tissue MET levels (p = 0.002) were associated with shorter OS. MET expression ranged from
2−∆∆Ct = 0.065 to 53.959 and high levels were defined as 2−∆∆Ct ≥ 5.554. The EGFR CTCs, miRNAs, and
other genes analyzed showed no statistical association. As previously observed with the RFS, neither
adjuvant chemotherapy nor post-operative radiotherapy had an impact on the OS (Supplementary Table
S4) (Figure 4D). The multivariate regression analysis revealed that the presence of CTC3 (HR = 10.8,
95% CI = 1.54–76.4, p = 0.017) and high AXL expression (HR = 15.7, 95% CI = 1.63–150.7, p = 0.017)
were the only independent prognostic factors for OS in adenocarcinoma patients (Table 2).
As reported for RFS, no CTC subgroup or experimental biomarkers were related to OS in the SCC
group (Supplementary Table S4). The relapse and N status were the only independent prognostic
factors for OS in SCC patients (Table 2).
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5. Discussion
The clinical value of CTCs is constantly growing, as they can assist in precision medicine-based
management of early resectable NSCLC patients by identifying those with an increased risk of recurrence.
In this prospective study, we reported that the presence of heterogeneous CTC subpopulations is
associated with tissue-specific genetic and miRNAs profiles in resected lung adenocarcinoma and how
the role of the combination of both factors can identify patients with shorter RFS and OS.
We observed that the different CTC subpopulations were correlated with gene and miRNAs
interactions in the tissue. Interestingly, miR-155 expression was inversely correlated with IL6R and
AXL, which were at the same time associated with the presence of EMT CTCs in adenocarcinoma.
This concurs with previous studies, which reported that IL-6R and AXL, essential promoters of
EMT in NSCLC through the STAT3 and the PI3K/AKT signaling pathways [31], are potential
targets repressed by miR-155 [32]. EMT phenotype was also correlated with the expression of
the Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which upregulates the EMT pathway [33]
and is an adverse prognostic factor in resected NSCLC [21]. Hereby, our study describes, for the
first time, how these genetic pathways could be involved in the dissemination of heterogeneous
subpopulations of CTCs in ADC patients. Thus, a low miR-155/high AXL–IL6R–GAPDH tissue
expression pathway might be involved in the release of CTCs with an EMT phenotype before surgery.
Furthermore, we studied the prognostic role of these CTC subpopulations and tissue biomarkers.
According to our results, the presence of CTCs after surgery increased the risk of a shorter RFS more
than 2-fold in ADC patients (HR = 2.51, 95% CI = 1.07–5.87, p = 0.034), regardless of adjuvant treatment.
On the contrary, no effect on RFS was seen in the SCC subpopulation (HR = 1.18, 95% CI = 0.45–3.12,
p = 0.733). Compared to advanced stages, there are only a few studies that have demonstrated the
prognostic role of CTCs in resectable NSCLC [9,34,35], including two previous publications from our
group [10,11].
In addition, we observed that the presence of CTCs at six months after surgery was a poor
prognostic factor for OS in ADC, increasing the risk more than 10-fold (HR = 10.8, 95% CI = 1.54–76.4,
p = 0.017). Interestingly, in these patients, high levels of AXL expression in tissue significantly decreased
OS (more 15-fold; HR = 15.7, 95% CI = 1.63–150.7, p = 0.017). To the best of our knowledge, this is the
first study that has reported the clinical impact of the presence of CTCs six months after surgery in the
mortality of ADC patients, with no influence of the adjuvant treatment. In accordance with previous
studies [23], we also confirmed that the overexpression of tissue AXL is a prognostic factor for survival
in completely resected ADC patients.
Interestingly, miRNAs were not prognostic factors either in ADC or in SCC subpopulations.
Moreover, we found that no CTC subpopulation or analyzed gene gave any prognostic value for RFS
or OS in our cohort of SCC patients. We hypothesize that the differences in the prognostic value of
the CTCs between both subtypes might be caused by the markers used in the isolation. Our study
based the identification of epithelial and EMT CTCs according to the presence of cytokeratin and
vimentin in both ADC and SCC patients. However, these subtypes differ in the molecular process of
dissemination and pathogenesis. This suggests the need to identify new markers for the isolation of
malignant subpopulations of CTCs in SCC, which could explain the differences in the aggressiveness
between these two NSCLC subtypes.
On the other hand, we found that the presence of EMT CTCs at baseline status in ADC patients
was associated with high N stage (p = 0.007), consistent with previous findings [36], relating the
presence of these subpopulations to malignant progression. In addition, as reported in previous
studies in early NSCLC [37], we found that EMT CTCs were associated with an increased risk of RFS
(HR = 2.3) and OS (HR = 1.6), but with non-statistically significant association, perhaps due to the
small sample size (EMT CTC1 detection performed in 22 ADC patients). Further studies including
larger populations will be needed to confirm these results and address the prognostic significance of
EMT CTCs in ADC patients.
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In the present study, we focused on AXL expression and EMT activation due to their important
biological roles in lung cancer. Our study confirmed the poor prognostic survival role of AXL
expression and showed a correlation between EMT activation on CTCs and malignant progression.
Studies have proven how AXL increases the resistance to platinum-based chemotherapy as well as
to EGFR targeted therapy in EMT cells [13]. In addition, AXL confers resistance to immunotherapy,
promoting immune evasion by avoiding natural killer-cell activation and reducing innate cell-mediated
anti-immune response. In lung adenocarcinoma, recent studies have confirmed that AXL inhibition
decreased the expression of PD-L1 and CXC chemokine receptor 6 (CXCR6), especially when EGFR
was mutated [38]. More specifically, CTCs expressing PD-L1 present partial EMT phenotype in NSCLC
and might represent a mechanism for immune escape [39]. The inhibition of AXL has been shown
to enhance immune response following radiotherapy, therefore, targeting AXL could have a dual
benefit, reducing EMT as well as activating the antitumor immune response [40]. All these data
suggest that AXL inhibition could increase the sensitivity to platinum-based chemotherapy as well as
anti-PD-1/PD-L1 therapies. Recently, immunotherapy has emerged as an effective treatment strategy
in advanced/metastatic NSCLC and is rapidly moving in the neo/adjuvant setting with promising
results [41]. Our study could provide the rationale for the inclusion of tissue AXL expression and CTC
EMT activation as potential biomarkers of activity for these agents in early stage adenocarcinoma. In
addition, these premises could open the door for combinations with AXL inhibitors in the adjuvant
setting with the intent to increase the outcomes of resected NSCLC.
6. Conclusions
Altogether, our study showed that the CTC presence one month after surgery was an independent
prognostic factor for RFS, and the CTC presence six months after surgery and the tissue AXL expression
were independent prognostic factors for OS in adenocarcinoma patients. Moreover, tissue AXL
expression and CTC EMT activation could potentially represent biomarkers for the stratification of
adenocarcinoma patients that might benefit from new adjuvant therapies.
7. Limitations of the Study
Although histological subtype populations were homogeneous, we consider that these results are
limited by the low number of patients. There can be also inherent methodological limitations, due
principally to the manual techniques used to analyze the presence of CTCs. Thus, to minimize bias
and methodological variations, we have herein adopted rigorous standardized assay methods and
the results were scored by two blinded independent well-trained clinical pathologists. Furthermore,
additional studies with larger clinical sample cohort size from different centers would be of value to
further validate our results.
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